Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | APR-246 in TP53 mutated MDS and AML

David Sallman • 3 Sep 2020
SOHO 2020
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes APR-246 Azacitidine Venetoclax

David Sallman, MD, H. Lee Moffitt Cancer Center, Tampa, FL, updates us on the use of APR-246, a p53 targeted therapy, evaluated with azacitidine in TP53 mutated MDS and acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from David Sallman

2:08
Hematological response to frontline treatment in LR-MDS is associated with better OS
David Sallman • 9 Dec 2023
1:58
Canakinumab plus darbepoetin in patients with LR-MDS following ESA failure
David Sallman • 9 Dec 2023
2:49
Front-line treatment options for HR-MDS: can we move past azacitidine?
David Sallman • 9 Dec 2023
Transplantation & immunotherapies
Charles Craddock et al. • 4 Sep 2023

Related Videos

3:05
The development of iNKT-CAR T-cells for hematological malignancies
Kanagaraju Ponnusamy • 29 Apr 2024
2:00
BTK degraders in CLL and lymphoma: a Phase I trial of NX-5948
Dima El-Sharkawi • 28 Apr 2024
2:04
Increasing awareness of germline predispositions to hematological malignancies in pediatric patients
Anupama Rao • 29 Apr 2024
0:57
The development of a UK AML registry
Priyanka Mehta • 22 Apr 2024
The content of VJHemOnc is intended for healthcare professionals